GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes

The triple-combination therapy (sitagliptin, glimepiride, and metformin) demonstrated superior efficacy in achieving glycemic control, as evidenced by significant reductions in HbA1c, fasting blood glucose (FBG), and postprandial plasma glucose (PPG). Furthermore, the therapy facilitated meaningful weight reduction, highlighting its clinical utility as a comprehensive therapeutic option for managing glycemic parameters in both T2DM with overweight and normal-weight patients.